1. Home
  2. PDS vs PHVS Comparison

PDS vs PHVS Comparison

Compare PDS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision Drilling Corporation

PDS

Precision Drilling Corporation

HOLD

Current Price

$70.27

Market Cap

918.1M

Sector

N/A

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDS
PHVS
Founded
1951
2015
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
918.1M
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PDS
PHVS
Price
$70.27
$25.82
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$99.00
$39.44
AVG Volume (30 Days)
89.9K
518.2K
Earning Date
10-22-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.98
N/A
Revenue
$1,316,232,437.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.89
N/A
P/E Ratio
$23.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.20
$11.51
52 Week High
$71.77
$29.80

Technical Indicators

Market Signals
Indicator
PDS
PHVS
Relative Strength Index (RSI) 68.52 54.34
Support Level $66.44 $23.79
Resistance Level $71.77 $25.44
Average True Range (ATR) 2.12 1.91
MACD 0.02 -0.17
Stochastic Oscillator 81.67 41.22

Price Performance

Historical Comparison
PDS
PHVS

About PDS Precision Drilling Corporation

Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: